A clinical trial found that combination therapy with IL-7 and immune checkpoint inhibitors significantly improved survival and response rates in NSCLC patients compared to using immune checkpoint inhibitors alone [90]. This evidence concerns the gene IL7 and non-small cell lung carcinoma.